REMINDER – TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

NEXT STORY
ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
PREV STORY
Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML

Company to terminate FOCUS study due to lack of clear efficacy signal in the ...

author_avatar
NASDAQ Market News

Orion publishes Half-Year Financial Report for January–June 2021 on Monday 19 July 2021

author_avatar
NASDAQ Market News

Sensus Healthcare Reports Third Quarter 2020 Financial Results

author_avatar
NASDAQ Market News